Access to anti-retroviral drugs, male in Tunisia

Tunisia: Access to anti-retroviral drugs, male was 28.0% in 2024. ◆ Volatile

Latest (2024)
28.0%
Change on year
up 12.0%
World rank
133rd
of 141 countries
All-time high
28.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Tunisia, 2000–2024

01020302000201220242000: 0 %2001: 2 %2002: 2 %2003: 3 %2004: 3 %2005: 4 %2006: 5 %2007: 5 %2008: 6 %2009: 7 %2010: 8 %2011: 9 %2012: 7 %2013: 8 %2014: 9 %2015: 10 %2016: 12 %2017: 12 %2018: 14 %2019: 16 %2020: 17 %2021: 18 %2022: 22 %2023: 25 %2024: 28 %

Source: UNAIDS estimates. Measured in %.

Analysis

Tunisia recorded 28.0% for access to anti-retroviral drugs, male in 2024. That is the highest value across all 25 years on record.

The figure is up 12.0% on the previous year and up 211.1% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Tunisia peaked at 28.0% in 2024 and was at its lowest, 0.0%, in 2000.

Tunisia ranks 133rd of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Tunisia, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Tunisia, 2000 to 2024.
Year % Change
2000 0.0%
2001 2.0%
2002 2.0% +0.0%
2003 3.0% +50.0%
2004 3.0% +0.0%
2005 4.0% +33.3%
2006 5.0% +25.0%
2007 5.0% +0.0%
2008 6.0% +20.0%
2009 7.0% +16.7%
2010 8.0% +14.3%
2011 9.0% +12.5%
2012 7.0% -22.2%
2013 8.0% +14.3%
2014 9.0% +12.5%
2015 10.0% +11.1%
2016 12.0% +20.0%
2017 12.0% +0.0%
2018 14.0% +16.7%
2019 16.0% +14.3%
2020 17.0% +6.2%
2021 18.0% +5.9%
2022 22.0% +22.2%
2023 25.0% +13.6%
2024 28.0% +12.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 3.7% 0.0% 7.0% 10
2010s 10.5% 7.0% 16.0% 10
2020s 22.0% 17.0% 28.0% 5

Countries ranked near Tunisia

  1. 130 Suriname 41.0% compare
  2. 131 Congo 40.0% compare
  3. 131 Ghana 40.0% compare
  4. 133 Djibouti 28.0% compare
  5. 133 Fiji 28.0% compare
  6. 136 Gambia 27.0% compare
  7. 136 Yemen 27.0% compare

See the full ranking of 160 places →

More gender data for Tunisia

All data for Tunisia →

Frequently asked questions

What is access to anti-retroviral drugs, male in Tunisia?
Access to anti-retroviral drugs, male in Tunisia was 28.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Tunisia?
The highest recorded value was 28.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Tunisia?
The lowest recorded value was 0.0% in 2000.
How does Tunisia rank for access to anti-retroviral drugs, male?
Tunisia ranks 133rd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Tunisia?
Over the last ten years it is up 211.1%. The long-run trend across the full record is volatile.
Where does this Tunisia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Tunisia. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/tunisia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/tunisia/">Access to anti-retroviral drugs, male in Tunisia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.